Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Maka Siamashvili & Stephen N. Davis. (2021) Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Review of Clinical Pharmacology 14:9, pages 1081-1089.
Read now
Read now
Basak Ozgen Saydam & Bulent Okan Yildiz. (2021) Weight management strategies for patients with PCOS: current perspectives. Expert Review of Endocrinology & Metabolism 16:2, pages 49-62.
Read now
Read now
Isabel Krug, Sarah Giles & Chiara Paganini. (2019) Binge eating in patients with polycystic ovary syndrome: prevalence, causes, and management strategies. Neuropsychiatric Disease and Treatment 15, pages 1273-1285.
Read now
Read now
Elizabeth Mary Lamos, Rana Malek & Stephen N. Davis. (2017) GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Review of Clinical Pharmacology 10:4, pages 401-408.
Read now
Read now
Articles from other publishers (45)
Lindsay R. Standeven, Kelsey Hannan, Bhuchitra Singh & Liisa Hantsoo. (2023) Polycystic Ovary Syndrome. Advances in Psychiatry and Behavioral Health 3:1, pages 91-101.
Crossref
Crossref
Frederikke Lindenberg DVM PhD, Ida Ulsø Bsc.med PhD, Gitte Juul Almind MD PhD, Marta Peña García, Emilie Færch Sømer & Svend Lindenberg Dr. Med.. (2023) GLP-1 analogue as a novel approach for fertility treatment: unravelling the therapeutic potential: A narrative review. Obstetrics & Gynecology International Journal 14:4, pages 120-122.
Crossref
Crossref
G. G. Zasypkin, T. I. Golikova, G. A. Matveev & A. Yu. Babenko. (2023) Effects of various weight-reducing drugs on eating behavior. Meditsinskiy sovet = Medical Council 17:9, pages 114-121.
Crossref
Crossref
Jiali Niu, Meiyin Lu & Bin Liu. (2023) Association between insulin resistance and abnormal menstrual cycle in Chinese patients with polycystic ovary syndrome. Journal of Ovarian Research 16:1.
Crossref
Crossref
Jacob E. Pruett, Damian G. Romero & Licy L. Yanes Cardozo. (2023) Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. Frontiers in Endocrinology 14.
Crossref
Crossref
Christodoula Kourtidou & Konstantinos Tziomalos. (2023) Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome. Biomedicines 11:2, pages 496.
Crossref
Crossref
Joana Nicolau, Antelm Pujol, Santiago Tofé, Aina Bonet & Apolonia Gil. (2022) Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity. Physiology & Behavior 257, pages 113967.
Crossref
Crossref
Karen E. Elkind-Hirsch, Neil Chappell, Donna Shaler, John Storment & Drake Bellanger. (2022) Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertility and Sterility 118:2, pages 371-381.
Crossref
Crossref
Krzysztof Bednarz, Karolina Kowalczyk, Marlena Cwynar, Dominika Czapla, Wiktor Czarkowski, Dominika Kmita, Artur Nowak & Paweł Madej. (2022) The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences 23:8, pages 4334.
Crossref
Crossref
Janet Treasure, Sevgi Bektas, Hiba Mutwalli, Namrata Dhopatkar & Hubertus Himmerich. (2022) Novel approaches to tackling emotional loss of control of eating across the weight spectrum. Proceedings of the Nutrition Society, pages 1-9.
Crossref
Crossref
Joana Nicolau, Luisa Ayala, Aina Bonet, Bárbara Manga, Josep María Muñoz, Joseba Olea & Apolonia Gil. (2022) Análogos de GLP1 en los pacientes con sobrepeso u obesidad durante el confinamiento. Medicina Clínica 158:3, pages 105-110.
Crossref
Crossref
Joana Nicolau, Luisa Ayala, Aina Bonet, Bárbara Manga, Josep María Muñoz, Joseba Olea & Apolonia Gil. (2022) GLP1 analogues among patients with overweight or obesity during lockdown. Medicina Clínica (English Edition) 158:3, pages 105-110.
Crossref
Crossref
Yang Yu, I. Diana Fernandez, Ying Meng, Wenjuan Zhao & Susan W. Groth. (2021) Gut hormones, adipokines, and pro- and anti-inflammatory cytokines/markers in loss of control eating: A scoping review. Appetite 166, pages 105442.
Crossref
Crossref
Xiaorui Lyu, Taibiao Lyu, Xue Wang, Huijuan Zhu, Hui Pan, Linjie Wang, Hongbo Yang & Fengying Gong. (2021) The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. International Journal of Endocrinology 2021, pages 1-11.
Crossref
Crossref
Józef Drzewoski & Markolf Hanefeld. (2021) The Current and Potential Therapeutic Use of Metformin—The Good Old Drug. Pharmaceuticals 14:2, pages 122.
Crossref
Crossref
Mohammed Altigani Abdalla, Harshal Deshmukh, Stephen Atkin & Thozhukat Sathyapalan. (2021) The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882198923.
Crossref
Crossref
Marie‐Christine Dubé, Martin D'Amours & S. John Weisnagel. (2020) Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes. Diabetes, Obesity and Metabolism 22:8, pages 1417-1424.
Crossref
Crossref
Lisa Wong, Lauren Stammers, Leonid Churilov, Sarah Price, Elif Ekinci & Priya Sumithran. (2020) Emotional eating in patients attending a specialist obesity treatment service. Appetite 151, pages 104708.
Crossref
Crossref
Georgios S. Papaetis, Panagiota K. Filippou, Kiriaki G. Constantinidou & Christina S. Stylianou. (2020) Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. Clinical Drug Investigation 40:8, pages 695-713.
Crossref
Crossref
Chan Hee Kim, Seung Joo Chon & Seon Heui Lee. (2020) Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: A systematic review and meta-analysis. Scientific Reports 10:1.
Crossref
Crossref
Daniela Romualdi, Valeria Versace & Antonio Lanzone. (2020) What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment. Therapeutic Advances in Reproductive Health 14, pages 263349412090870.
Crossref
Crossref
Abigail Sharpe, Lara C Morley, Thomas Tang, Robert J Norman & Adam H Balen. (2019) Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Beata Banaszewska, Leszek Pawelczyk & Robert Spaczynski. (2019) Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome. Reproductive Biology 19:4, pages 309-315.
Crossref
Crossref
Lu Shen, Yuan Chen, Jing Cheng, Suzhen Yuan, Su Zhou, Wei Yan, Junfeng Liu, Aiyue Luo & Shixuan Wang. (2019) CCL5 secreted by senescent theca‐interstitial cells inhibits preantral follicular development via granulosa cellular apoptosis. Journal of Cellular Physiology 234:12, pages 22554-22564.
Crossref
Crossref
Mojca Jensterle, Andrej Janez, Eric Fliers, J Hans DeVries, Eda Vrtacnik-Bokal & Sarah E Siegelaar. (2019) The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Human Reproduction Update 25:4, pages 504-517.
Crossref
Crossref
Alison J. Dawson, Thozhukat Sathyapalan, Rebecca Vince, Anne-Marie Coady, Ramzi A. Ajjan, Eric S. Kilpatrick & Stephen L. Atkin. (2019) The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. Frontiers in Endocrinology 10.
Crossref
Crossref
Beatriz T. Meneguetti, Marlon H. Cardoso, Camila F.A. Ribeiro, Mário R. Felício, Ingrid B. Pinto, Nuno C. Santos, Cristiano M.E. Carvalho & Octávio L. Franco. (2019) Neuropeptide receptors as potential pharmacological targets for obesity. Pharmacology & Therapeutics 196, pages 59-78.
Crossref
Crossref
F.‐F. Wang, Y. Wu, Y.‐H. Zhu, T. Ding, R. L. Batterham, F. Qu & P. J. Hardiman. (2018) Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta‐analysis. Obesity Reviews 19:10, pages 1424-1445.
Crossref
Crossref
Mojca Jensterle Sever, Simona Ferjan & Andrej Janez. 2018. Debatable Topics in PCOS Patients. Debatable Topics in PCOS Patients.
Susan L. McElroy, Nicole Mori, Anna I. Guerdjikova & Paul E. KeckJrJr. (2018) Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. Medical Hypotheses 111, pages 90-93.
Crossref
Crossref
Sofia Dias, Sílvia Paredes & Laura Ribeiro. (2018) Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. International Journal of Endocrinology 2018, pages 1-21.
Crossref
Crossref
Marie‐Christine Dubé, Martin D'Amours & S. John Weisnagel. (2017) Beyond glycaemic control: A cross‐over, double‐blinded, 24‐week intervention with liraglutide in type 1 diabetes. Diabetes, Obesity and Metabolism 20:1, pages 178-184.
Crossref
Crossref
Signe Frøssing, Malin Nylander, Elizaveta Chabanova, Jan Frystyk, Jens J. Holst, Caroline Kistorp, Sven O. Skouby & Jens Faber. (2017)
Effect of liraglutide on ectopic fat in polycystic ovary syndrome:
A
randomized clinical trial
. Diabetes, Obesity and Metabolism 20:1, pages 215-218.
Crossref
Crossref
Lara C Morley, Thomas Tang, Ephia Yasmin, Robert J Norman & Adam H Balen. (2017) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2018:2.
Crossref
Crossref
Malin Nylander, Signe Frøssing, Helle V. Clausen, Caroline Kistorp, Jens Faber & Sven O. Skouby. (2017) Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reproductive BioMedicine Online 35:1, pages 121-127.
Crossref
Crossref
Andrej Janez & Mojca Jensterle. (2017) Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome. Journal of Diabetes and Obesity 4:1, pages 1-3.
Crossref
Crossref
W. Timothy Garvey, Jeffrey I. Mechanick, Elise M. Brett, Alan J. Garber, Daniel L. Hurley, Ania M. Jastreboff, Karl Nadolsky, Rachel Pessah-Pollack & Raymond Plodkowski. (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocrine Practice 22, pages 1-203.
Crossref
Crossref
Piper L. Miguelgorry & Ed J. Hendricks. (2016) Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician’s Perspective. Advances in Therapy 33:7, pages 1262-1266.
Crossref
Crossref
Mitra Niafar, Leili Pourafkari, Jahan Porhomayon & Nader Nader. (2015) A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Archives of Gynecology and Obstetrics 293:3, pages 509-515.
Crossref
Crossref
Tzuchun Lin, Shengxian Li, Hua Xu, Huan Zhou, Rilu Feng, Wei Liu, Yun Sun & Jing Ma. (2015) Gastrointestinal hormone secretion in women with polycystic ovary syndrome: an observational study. Human Reproduction 30:11, pages 2639-2644.
Crossref
Crossref
Christian Roth. (2015) Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity Intervention. Journal of Clinical Medicine 4:9, pages 1774-1797.
Crossref
Crossref
Negar Naderpoor, Soulmaz Shorakae, Barbora de Courten, Marie L. Misso, Lisa J Moran & Helena J. Teede. (2015) Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human Reproduction Update 21:5, pages 560-574.
Crossref
Crossref
Mojca Jensterle, Boštjan Pirš, Katja Goričar, Vita Dolžan & Andrej Janež. (2015) Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. European Journal of Clinical Pharmacology 71:7, pages 817-824.
Crossref
Crossref
Wendy Vitek, Snigdha Alur & Kathleen M. Hoeger. (2015) Off-label drug use in the treatment of polycystic ovary syndrome. Fertility and Sterility 103:3, pages 605-611.
Crossref
Crossref
Fátima Higuera-de la Tijera. (2015) Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World Journal of Hepatology 7:10, pages 1297.
Crossref
Crossref